Enabling scalable and cost-efficient future healthcare solutions with autonomous health monitoring is the most important driver for Medicubex, headquartered in Helsinki, Finland. Innokas Medical is...
Recent Posts
Innokas Medical participated in the project where the regulatory framework for NTNU’s new set of reagents were created.
FlowOx 2.0, developed in co-creation between Norwegian company Otivio AS and Innokas Medical, is a clinically promising, patented and cost-efficient home treatment solution for Peripheral Arterial...
Headquartered in Helsinki, Finland, MEGIN is the global leader for magnetoencephalography (MEG) technology used for their non-invasive functional brain mapping solution. A long-term collaboration...
With their next-generation innovation, Synoste aims to renew surgical treatment related to bone deformities. Innokas Medical is involved in this mission by being one of Synoste's co-creation partners...
WellO2, innovation developed by the Finnish company WellO2 Oy (formerly known as Hapella Oy), is a breathing exercise device that strengthens and cleanses the lungs. The mission of the company is to...
Norwegian healthtech innovator Augere Medical AS has selected Innokas Medical as their co-creation partner to offer quality and regulatory as well as design and development support to bring their...
The objective of Finnish-based IVD company Aidian is to promote efficient and fluent healthcare by developing and manufacturing reliable, fast and easy to use diagnostic tests for point of care....
Danish company Samplix ApS selected Innokas Medical to co-create the novel Xdrop™ instrument for droplet-based PCR-free enrichment of genomic regions.
